Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. OMCL
stocks logo

OMCL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
313.39M
+2.12%
0.489
-18.54%
281.20M
+4.28%
0.310
+19.23%
302.10M
+3.97%
0.440
-2.22%
Estimates Revision
The market is revising Upward the revenue expectations for Omnicell, Inc. (OMCL) for FY2025, with the revenue forecasts being adjusted by 2.93% over the past three months. During the same period, the stock price has changed by 23.36%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.93%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+7.77%
In Past 3 Month
Stock Price
Go Up
up Image
+23.36%
In Past 3 Month
Wall Street analysts forecast OMCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMCL is 40.67 USD with a low forecast of 34.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast OMCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMCL is 40.67 USD with a low forecast of 34.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 39.610
sliders
Low
34.00
Averages
40.67
High
45.00
Current: 39.610
sliders
Low
34.00
Averages
40.67
High
45.00
Benchmark
NULL -> Buy
maintain
$40 -> $45
2025-10-31
Reason
Benchmark
Price Target
$40 -> $45
2025-10-31
maintain
NULL -> Buy
Reason
Benchmark raised the firm's price target on Omnicell to $45 from $40 and keeps a Buy rating on the shares. Omnicell's Q3 upside and Q4 guidance provide further evidence that the XTExtend and Amplify product offerings launched late last year are gaining increasing traction, the analyst tells investors.
Piper Sandler
Overweight
downgrade
$57 -> $55
2025-08-11
Reason
Piper Sandler
Price Target
$57 -> $55
2025-08-11
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Omnicell to $55 from $57 and keeps an Overweight rating on the shares. The firm notes the company raised 2025 guidance on Q2 strength across both segments and a dynamic China tariff situation. Piper updates its product gross margin forecast for the second half of 2025 and 2026 to reflect management's latest commentary and the expectation that mitigation efforts eliminate effectively all China tariff impact by Q4 2026.
Wells Fargo
Stan Berenshteyn
Overweight
maintain
$37 -> $40
2025-07-21
Reason
Wells Fargo
Stan Berenshteyn
Price Target
$37 -> $40
2025-07-21
maintain
Overweight
Reason
Wells Fargo analyst Stan Berenshteyn raised the firm's price target on Omnicell to $40 from $37 and keeps an Overweight rating on the shares. The firm raises its 2025 adjusted EBITDA estimate above guided midpoint on a more favorable tariff setup post-90 day pause than we previously contemplated.
BofA
Neutral
downgrade
$34 -> $32
2025-07-14
Reason
BofA
Price Target
$34 -> $32
2025-07-14
downgrade
Neutral
Reason
BofA lowered the firm's price target on Omnicell to $32 from $34 and keeps a Neutral rating on the shares. BofA appreciates Omnicell's leading position in a duopolistic pharmacy automation market, but limited visibility into components of product revenue growth creates uncertainty near-term, the analyst tells investors in a research note.
Wells Fargo
Overweight
maintain
$35 -> $37
2025-05-23
Reason
Wells Fargo
Price Target
$35 -> $37
2025-05-23
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Omnicell to $37 from $35 and keeps an Overweight rating on the shares following the company's improved guidance outlook. While tariff risks remain fluid, the firm believes trade talks will likely steer outcomes toward the lower end of the risk range, supporting a more optimistic stance.
BofA
Allen Lutz
Neutral
maintain
$30 -> $34
2025-05-23
Reason
BofA
Allen Lutz
Price Target
$30 -> $34
2025-05-23
maintain
Neutral
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Omnicell Inc (OMCL.O) is 23.02, compared to its 5-year average forward P/E of 31.53. For a more detailed relative valuation and DCF analysis to assess Omnicell Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
31.53
Current PE
23.02
Overvalued PE
43.16
Undervalued PE
19.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
19.61
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
27.02
Undervalued EV/EBITDA
12.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.83
Current PS
0.00
Overvalued PS
4.48
Undervalued PS
1.19
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

OMCL News & Events

Events Timeline

(ET)
2025-10-30
06:52:19
Omnicell projects 2025 non-GAAP EPS between $1.63 and $1.73, surpassing consensus estimate of $1.55.
select
2025-10-30
06:51:25
Omnicell projects Q4 non-GAAP EPS between 40c and 50c, in line with consensus of 48c.
select
2025-10-30
06:50:23
Omnicell announces Q3 non-GAAP EPS of 51 cents, surpassing consensus estimate of 36 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-02Newsfilter
Omnicell to Host Innovation Update and Investor Q&A at ASHP Midyear Meeting
  • Innovation Update Session: Omnicell will host an Innovation Update on December 8, 2025, during the ASHP Midyear Clinical Meeting in Las Vegas, aimed at showcasing its latest advancements in transforming pharmacy and nursing care delivery models, which is expected to attract significant attention from industry stakeholders.
  • Investor Q&A Session: The Q&A session will take place the same day at 4 PM, offering both in-person and webcast options, designed to enhance interaction with investors and further boost company transparency and investor confidence.
  • Leadership Team Presentation: Omnicell's executive team, including founder and CEO Randall Lipps, will speak at the event, highlighting the company's leadership in smart pharmacy solutions and emphasizing its impact within the healthcare sector.
  • Integration of Technology and Services: Since 1992, Omnicell has been committed to delivering comprehensive solutions through robotics, smart devices, intelligent software workflows, and data analytics, helping healthcare facilities achieve cost savings and efficiency improvements while advancing the industry's vision of the Autonomous Pharmacy.
[object Object]
Preview
6.5
11-27NASDAQ.COM
Wall Street Analysts Predict Omnicell (OMCL) May Rise by 30.93%: Important Insights Before You Invest

  • Stock Performance and Analyst Predictions: Omnicell (OMCL) shares have risen 24% recently, with a mean price target of $48 suggesting a potential upside of 30.9%, although estimates vary widely among analysts.

  • Skepticism Towards Price Targets: Investors should approach price targets with caution, as they can often be misleading due to analysts' potential biases and business incentives, despite some agreement indicating a possible stock price movement.

  • Earnings Estimate Revisions: Analysts have shown increasing optimism about Omnicell's earnings, with a 17.5% increase in the Zacks Consensus Estimate, which historically correlates with positive stock price movements.

  • Investment Strategy Considerations: While the consensus price target may not be entirely reliable, the direction it suggests, combined with strong earnings revisions, could provide a useful guide for investors considering OMCL.

[object Object]
Preview
9.5
10-31NASDAQ.COM
Reasons Behind Omnicell's Stock Surge Today

  • Omnicell's Q3 Performance: Omnicell reported a strong third-quarter performance with revenue of $311 million, exceeding analyst estimates, despite a slight decline in net income to $24 million.

  • Stock Market Reaction: Following the earnings report, Omnicell's shares surged nearly 14%, contrasting with a 1% drop in the S&P 500 on the same day.

  • Future Guidance: The company raised its revenue guidance for the year to between $1.18 billion and $1.19 billion, with adjusted earnings per share expected to be between $1.63 and $1.73 for 2025.

  • Investment Considerations: Despite its strong performance, Omnicell was not included in the Motley Fool Stock Advisor's list of top stocks to buy, which has historically outperformed the market significantly.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Omnicell Inc (OMCL) stock price today?

The current price of OMCL is 39.61 USD — it has decreased -2.15 % in the last trading day.

arrow icon

What is Omnicell Inc (OMCL)'s business?

Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.

arrow icon

What is the price predicton of OMCL Stock?

Wall Street analysts forecast OMCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMCL is 40.67 USD with a low forecast of 34.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Omnicell Inc (OMCL)'s revenue for the last quarter?

Omnicell Inc revenue for the last quarter amounts to 310.63M USD, increased 9.99 % YoY.

arrow icon

What is Omnicell Inc (OMCL)'s earnings per share (EPS) for the last quarter?

Omnicell Inc. EPS for the last quarter amounts to 0.12 USD, decreased -36.84 % YoY.

arrow icon

What changes have occurred in the market's expectations for Omnicell Inc (OMCL)'s fundamentals?

The market is revising Upward the revenue expectations for Omnicell, Inc. (OMCL) for FY2025, with the revenue forecasts being adjusted by 2.93% over the past three months. During the same period, the stock price has changed by 23.36%.
arrow icon

How many employees does Omnicell Inc (OMCL). have?

Omnicell Inc (OMCL) has 3670 emplpoyees as of December 05 2025.

arrow icon

What is Omnicell Inc (OMCL) market cap?

Today OMCL has the market capitalization of 1.78B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free